probenecid has been researched along with Soft Tissue Infections in 2 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
Soft Tissue Infections: Infections of non-skeletal tissue, i.e., exclusive of bone, ligaments, cartilage, and fibrous tissue. The concept is usually referred to as skin and soft tissue infections and usually subcutaneous and muscle tissue are involved. The predisposing factors in anaerobic infections are trauma, ischemia, and surgery. The organisms often derive from the fecal or oral flora, particularly in wounds associated with intestinal surgery, decubitus ulcer, and human bites. (From Cecil Textbook of Medicine, 19th ed, p1688)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To review the pharmacokinetic and clinical evidence for the use of once-daily cefazolin and probenecid in the treatment of skin and soft tissue infections (SSTI)." | 8.82 | Once-daily cefazolin and probenecid for skin and soft tissue infections. ( Cox, VC; Zed, PJ, 2004) |
| "To review the pharmacokinetic and clinical evidence for the use of once-daily cefazolin and probenecid in the treatment of skin and soft tissue infections (SSTI)." | 4.82 | Once-daily cefazolin and probenecid for skin and soft tissue infections. ( Cox, VC; Zed, PJ, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dalen, D | 1 |
| Fry, A | 1 |
| Campbell, SG | 1 |
| Eppler, J | 1 |
| Zed, PJ | 2 |
| Cox, VC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intravenous Cefazolin Plus Oral Probenecid vs. Oral Cephalexin for the Treatment of Cellulitis: a Randomized Controlled Trial[NCT01029782] | Phase 2 | 206 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01029782)
Timeframe: 72 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| IV Cefazolin Plus Oral Probenecid and Placebo Cephalexin | 6 |
| Oral Cephalexin and Saline IV Plus Probenecid Placebo | 4 |
1 review available for probenecid and Soft Tissue Infections
| Article | Year |
|---|---|
Once-daily cefazolin and probenecid for skin and soft tissue infections.
Topics: Anti-Bacterial Agents; Biological Availability; Cefazolin; Half-Life; Humans; Male; Probenecid; Rand | 2004 |
1 other study available for probenecid and Soft Tissue Infections
| Article | Year |
|---|---|
Intravenous cefazolin plus oral probenecid versus oral cephalexin for the treatment of skin and soft tissue infections: a double-blind, non-inferiority, randomised controlled trial.
Topics: Adjuvants, Pharmaceutic; Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Canada; Cefazolin | 2018 |